famitinib + cisplatin

**Famitinib + cisplatin** is a combination drug regimen used in oncology research, particularly for the treatment of solid tumors such as gastric cancer, urothelial carcinoma, and potentially other advanced cancers. **Famitinib** is an orally available multi-targeted receptor tyrosine kinase inhibitor that specifically inhibits stem cell factor receptor (c-Kit), vascular endothelial growth factor receptors (VEGFR2, VEGFR3), platelet-derived growth factor receptor (PDGFR), FMS-like tyrosine kinases (Flt1, Flt3), and fibroblast growth factor receptors (FGFR)[2][4]. This inhibition targets multiple signaling pathways involved in tumor angiogenesis, proliferation, and survival. **Cisplatin** is a platinum-based chemotherapy agent that induces DNA crosslinking and damage, leading to cell apoptosis in rapidly dividing tumor cells. The combination is under investigation for synergistic antitumor effects, with famitinib blocking pro-survival and angiogenic signals while cisplatin causes cytotoxic DNA damage[6]. Clinical and preclinical studies indicate that combining these agents may have increased efficacy compared to monotherapy, depending on the scheduling of administration.

Other names

famitinib + cisplatin